We are comparing Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Checkpoint Therapeutics Inc. (NASDAQ:CKPT) on their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. They both are Biotechnology companies, competing one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ultragenyx Pharmaceutical Inc.||51.49M||75.72||197.61M||-3.90||0.00|
|Checkpoint Therapeutics Inc.||N/A||137.96||30.67M||-1.16||0.00|
Table 1 showcases the top-line revenue, earnings per share and valuation of Ultragenyx Pharmaceutical Inc. and Checkpoint Therapeutics Inc.
Table 2 represents Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Checkpoint Therapeutics Inc. (NASDAQ:CKPT)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ultragenyx Pharmaceutical Inc.||-383.78%||-29.3%||-25.4%|
|Checkpoint Therapeutics Inc.||0.00%||-139%||-104.3%|
The Current Ratio and a Quick Ratio of Ultragenyx Pharmaceutical Inc. are 7 and 6.9. Competitively, Checkpoint Therapeutics Inc. has 3.5 and 3.5 for Current and Quick Ratio. Ultragenyx Pharmaceutical Inc.’s better ability to pay short and long-term obligations than Checkpoint Therapeutics Inc.
The Recommendations and Ratings for Ultragenyx Pharmaceutical Inc. and Checkpoint Therapeutics Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ultragenyx Pharmaceutical Inc.||0||3||6||2.67|
|Checkpoint Therapeutics Inc.||0||0||0||0.00|
Ultragenyx Pharmaceutical Inc.’s consensus target price is $70.78, while its potential upside is 3.68%.
Insider and Institutional Ownership
Roughly 0% of Ultragenyx Pharmaceutical Inc. shares are owned by institutional investors while 11.2% of Checkpoint Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 0.4% of Ultragenyx Pharmaceutical Inc.’s shares. On the other hand, insiders owned about 9.4% of Checkpoint Therapeutics Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ultragenyx Pharmaceutical Inc.||4.21%||33.9%||19.9%||-21.29%||36.36%||51.89%|
|Checkpoint Therapeutics Inc.||8.9%||-20.1%||36.3%||-19.9%||-27.32%||68.13%|
For the past year Ultragenyx Pharmaceutical Inc.’s stock price has smaller growth than Checkpoint Therapeutics Inc.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude ChildrenÂ’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.